Skip to contentD
DNA X, Inc.
D
SONMDNA X, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$15.26M$15.26Mderived+13.6% vs Q4 2023 Net Income-$21.61M-$21.61MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
DNA X, Inc. · CIK 1178697 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$183,000N/M Operating Incomederived-$22,104,000N/M Operating Cash Flowderived-$4,509,000N/M Free Cash Flowderived-$4,517,000N/M Margins · derivedGross margin-1.2%−39.3 pt vs Q4 2023
Operating margin-144.8%−135.5 pt vs Q4 2023
Net margin-141.6%−131.5 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 31, 2025 · 90 d after period end